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titis Media: Why Is it so Difﬁcult to Treat or Prevent?
. Navarro-Locsin
Pediatric Otorhinolaryngologist, St. Luke’s Medical Center,
uezon City, Philippines
titis media (OM), one of the most common childhood dis-
ases, is a polymicrobial disease encompassing a spectrum
f ear conditions that can lead to complications such as
astoiditis, invasive disease and hearing loss. Streptococ-
us pneumoniae and non-typable Haemophilus inﬂuenzae
NTHi) account for up to 80% of cases of bacterial acute
M (AOM) worldwide. There is a direct relationship between
arly nasopharyngeal colonisation by S. pneumonia and NTHi
nd early ﬁrst episodes of AOM, and failure to eradicate
hese pathogens (particularly NTHi) completely from the
iddle ear is associated with treatment failure.1 Further-
ore, over 50% of H. inﬂuenzae isolates from patients
ith recurrent and refractory OM produce b-lactamase and
re intrinsically resistant to ampicillin and amoxicillin, the
ainstays of treatment.
Accurate diagnosis of OM aetiology in young children is
ften difﬁcult, so AOM is usually treated empirically with
ntibiotics without identifying the causative pathogen. Such
on-targeted therapy contributes to treatment failure and
ncreasing antibiotic resistance. Despite treatment guide-
ines that call for watchful waiting, AOM is the leading
ndication for antibiotic prescription in many developed
ountries.2
Preventing the ﬁrst episode of AOM is probably the
ptimal approach to reducing the burden of OM. The pneu-
ococcal conjugate vaccine (PCV)-7 has had modest success
gainst all-cause OM,3 possibly because it targets only S.
neumoniae. Post-PCV-7, an increase in the proportion of
OM cases attributable to NTHi has been observed.4,5 The
neumococcal Otitis Efﬁcacy Trial (POET) showed that the
1-valent pneumococcal H. inﬂuenzae protein D - conju-
ate vaccine candidate reduced 35.3% of NTHi-attributable
nd 57.6% of S. pneumoniae-attributable AOM cases, result-
ng in a clinically relevant 33.6% prevention of overall AOM
pisodes.6 Taking into account the dynamics of nasopha-
yngeal colonisation by S. pneumoniae and NTHi, a dual
athogen vaccine like the protein D conjugate vaccine, cou-
led with judicious antibiotic treatment, could substantially
educe the burden of AOM.
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reventing Pneumonia: Lessons and Future Implications
. Dagan
Beer Sheva University, Beer Sheva, Israel
neumonia is the leading killer of children worldwide.1
treptococcus pneumoniae and Haemophilus inﬂuenzae
ype b (Hib) are the leading causes of bacterial pneumonia
n young children, with S. pneumoniae being the most com-
on cause. The role of other bacteria such as non-typable
. inﬂuenzae (NTHi) in childhood pneumonia is not clear.
Hib conjugate vaccines almost eliminated Hib disease in
egions where they were introduced into the national immu-
isation programme, and they demonstrated protective
fﬁcacy against Hib bactaeremic pneumonia [69% (3—90%;
5% CI)].2 Seven- and nine-valent pneumococcal conjugate
accines (PCVs) reduced the incidence of (and hospitali-
ation caused by) vaccine-serotype pneumonia in children
ged less than 2 years.3 Additionally, the PCVs reduced
ll-cause pneumonia in vaccinees and their contacts (herd
mmunity).4 The PCVs also reduced rates of disease caused
y antibiotic-resistant S. pneumoniae.5
The characteristics of Hib and pneumococcal conju-
ate vaccines thought to be associated with protection
gainst pneumonia are multi-factorial. Vaccine induction
f functional protective immunity is critical for ade-
uate protection against pneumonia, as is the induction
f immunological memory. For a new conjugate vaccine, a
imilar immunogenicity proﬁle to existing vaccines that are
ffective against pneumonia may suggest similar efﬁcacy. A
accine class effect could therefore be envisaged providing
everal criteria are met, such as adequate opsonophago-
ytic titres and anti-pneumococcal IgG concentrations, and
oostability. Under a vaccine class effect, notwithstanding
he caveats pertaining to it, a new candidate PCV such as
he Pneumococcal Haemophilus inﬂuenzae Protein D - Con-
ugate Vaccine (PHiD-CV) might also be expected to offer
rotection against pneumonia.
eferences
1. Bryce, et al. Lancet 2005.
2. Obonyo, et al. Eur J Microbiol Infect Dis 2006.
3. Lucero, et al. Cochrane Database Syst Rev 2004.
4. Grijalva, et al. Lancet 2007.
5. Whitney, et al. N Engl J Med 2003.
oi:10.1016/j.ijid.2008.05.050
nfectious Diarrhea and Enteric Fever (invited)
.001
lose Encounters of the ETEC-type
. Cravioto ∗, F. QadrilICDDR, B, Dhaka, Bangladesh
nterotoxigenic Escherichia coli (ETEC) is a multivalent
athogenic organism that has been sub-classiﬁed into differ-
nt phenotypic groups based on the type of exoproteins it
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produces. These include enterotoxins and colonization fac-
tors apart from other antigens like the lipopolysaccharide
(LPS), which are part of the ‘O’ antigen. Over 100 types
of ‘O’ groups have been detected in ETEC strains in com-
bination with different ﬂagellar (H) antigens, that together
make the serotype (O:H) of the bacteria. Although exten-
sive efforts have been made to determine the prevalence of
the toxins and colonization factors in ETEC strains isolated
in different regions of the world, relatively little is known
about the serotype of the bacteria circulating in different
countries, especially those that are prevalent at this time.
Recent epidemiological studies have shown that ETEC
strains from different regions differ in their phenotypic char-
acteristics. These ﬁndings are important to determine which
vaccines would be suitable for use in one region but not in
another as a measure of protection against ETEC infections.
ETEC isolated from two geographically different locations,
Mexico and Bangladesh, have been characterized for their
‘O’ and ‘H’ antigens as well as for their enterotoxin types
and colonization factor production. Overall a variety of
ETEC phenotypes were found to be present in both set-
tings. Twelve serotypes were common in both settings. A few
serogroups were only present in isolates from Bangladesh
(O20, O115, O126, O128, O114), while others were present
only in strains isolated in Mexico (O103, O170, O22). The pre-
dominant colonization factors in both settings were CFA/I,
CS5+CS6, CS6 as well as CS1+CS2/CS3. Colonization factors
were produced by strains belonging to a few ‘O’ serogroups,
CFA/I (O126 and O128), CS5+CS6 (O115 and O167), CS6
(O169), CS1+CS2/CS3 (O6). Based on these results, formu-
lation of an effective multivalent ETEC vaccine will have to
include not only the major colonization factors and LT tox-
oid but also the LPS of important serogroups. An inactivated
killed ETEC vaccine that has undergone extensive testing
includes strains of serogroups O6, O25, O78 and O167. Based
on the present data this vaccine would in addition need the
incorporation of strains belonging to serogroups O115 and
O126 to be more effective in the protection against the most
common cause of bacterial diarrhea in early childhood and
the second most predominant cause of diarrhea in adults
in endemic countries, including tourists travelling to these
areas.
doi:10.1016/j.ijid.2008.05.051
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Typhoid Vaccines as Routine Public Health Tools for
Developing Countries: An Idea Whose Time Has Come
J. Clemens
International Vaccine Institute, Seoul, Republic of Korea
Despite the availability of two internationally licensed,
newer generation typhoid vaccines that are safe and effec-
tive and despite an annual global typhoid mortality burden
estimated at over 200,000 deaths, typhoid vaccines are not
routinely used as public health interventions in develop-
ing countries with high typhoid burdens. Although there are
multiple reasons for the failure to introduce these vaccines
into public health programs for the poor, a gap in evi-
dence to inform vaccine policy is a major factor. To address
this gap in evidence, the International Vaccine Institute,
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ith the support of the Bill and Melinda Gates Foundation,
as coordinated a multi-country, multidisciplinary program
f research, called the Diseases of the Most Impoverished
DOMI) Program, to inform policy about typhoid vaccine
ntroduction in Asia. This research program, which has been
ndertaken in Bangladesh, China, India, Indonesia, Pakistan,
nd Vietnam, has demonstrated the burden of typhoid fever
o be high, but geographically heterogeneous. The research
as also demonstrated a high ﬁnancial cost associated with
yphoid fever, and a modest cost of purchasing and deliv-
ring one of the two currently available, internationally
icensed typhoid vaccines (Vi polysaccharide). Demonstra-
ion projects with Vi vaccine have shown that the vaccine is
easibly delivered in mass immunization campaigns in both
chool and community settings, and when delivered in these
ampaigns the vaccine confers both direct and herd protec-
ion. As well, there is a high population demand for a vaccine
ith the cost and characteristics of Vi polysaccharide, and
ven a willingness on the part of developing country popu-
ations to pay for this vaccine, particularly for vaccination
f children. In aggregate, these ﬁndings have helped to
otivate a recently published, strengthened WHO recom-
endation for routine typhoid vaccination in settings with
igh typhoid disease burdens.
oi:10.1016/j.ijid.2008.05.052
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he New Emerging Strain of Cholera: One Step Ahead of
enomics
. Balakrish Nair
National Institute of Cholera and Enteric Diseases, Kolkata,
ndia
remarkable event in recent years has been the emergence
f strains of Vibrio cholerae O1 that possess traits of both
he classical and El Tor biotypes. These strains were ﬁrst
ncountered from sporadic cases of cholera isolated from
992 onwards in Matlab, Bangladesh. Phenotypic and geno-
ypic traits failed to categorize these strains into classical
r El Tor biotype and were designated as the Matlab vari-
nts. The Matlab variants assumed greater signiﬁcance when
trains of V. cholerae O1 isolated from Beira, Mozambique
n 2005 displayed typical traits of the El Tor biotype but car-
ied the classical CTX prophage. A more recent analysis of
. cholerae O1 strains isolated in Bangladesh during the past
our and a half decades revealed that from 2001 onwards
ll strains associated with cholera belonged to the El Tor
iotype but produced classical cholera toxin (CT) which was
ifferent from the prototype El Tor biotype that produced
l Tor CT. This new variant of the El Tor biotype is now
ominant in several other countries. At this time, it is not
ertain whether the change in CT subtype in the El Tor strains
ill enhance their epidemic potential. Given that there are
ifferences between the classical and El Tor biotypes, the
election of the El Tor biotype which produces classical CT
ould seem to indicate an evolutionary optimization of the
l Tor biotype and represents a new more efﬁcient emerging
orm of the El Tor biotype. Under the cholera surveillance
rogram of the International Centre for Diarrheal Disease
esearch in Bangladesh, an increasing trend in the number
